(Q38005950)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Ryo C. Yanagita

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Yu Nakagawa

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

publication date

9 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

Medicinal Research Reviews

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

518-535

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions

30 January 2020

cites work

1 reference

Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein

21 January 2018

1 reference

Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system

21 January 2018

1 reference

Protein kinase C and other diacylglycerol effectors in cancer

21 January 2018

1 reference

Targeting the protein kinase C family: are we there yet?

21 January 2018

1 reference

Protein kinase C as a therapeutic target

21 January 2018

1 reference

PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice.

21 January 2018

1 reference

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

21 January 2018

1 reference

Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

Protein kinase C epsilon suppresses Abeta production and promotes activation of alpha-secretase.

21 January 2018

1 reference

Role of protein kinase Calpha in the regulated secretion of the amyloid precursor protein

21 January 2018

1 reference

Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

21 January 2018

1 reference

Characterization of the interaction of phorbol esters with the C1 domain of MRCK (myotonic dystrophy kinase-related Cdc42 binding kinase) alpha/beta

21 January 2018

1 reference

The protein kinase complement of the human genome

21 January 2018

1 reference

The chemistry and biology of the bryostatin antitumour macrolides

21 January 2018

1 reference

Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin

21 January 2018

1 reference

A phase II study of bryostatin 1 in metastatic malignant melanoma

21 January 2018

1 reference

A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

21 January 2018

1 reference

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant.

21 January 2018

1 reference

Evidence for the biosynthesis of bryostatins by the bacterial symbiont "Candidatus Endobugula sertula" of the bryozoan Bugula neritina

21 January 2018

1 reference

bryA: an unusual modular polyketide synthase gene from the uncultivated bacterial symbiont of the marine bryozoan Bugula neritina

21 January 2018

1 reference

Total synthesis of bryostatin 16 using atom-economical and chemoselective approaches

21 January 2018

1 reference

The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.

21 January 2018

1 reference

Function oriented synthesis: the design, synthesis, PKC binding and translocation activity of a new bryostatin analog

21 January 2018

1 reference

Function-oriented synthesis, step economy, and drug design

21 January 2018

1 reference

Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C

21 January 2018

1 reference

The practical synthesis of a novel and highly potent analogue of bryostatin

21 January 2018

1 reference

Efficient synthetic access to a new family of highly potent bryostatin analogues via a Prins-driven macrocyclization strategy

21 January 2018

1 reference

Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: bryostatin look-alikes that mimic phorbol ester function

21 January 2018

1 reference

Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters

21 January 2018

1 reference

The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses

21 January 2018

1 reference

The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival

21 January 2018

1 reference

Tumor promotion by depleting cells of protein kinase C delta

21 January 2018

1 reference

Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence

21 January 2018

1 reference

Non-equivalent roles for the first and second zinc fingers of protein kinase Cdelta. Effect of their mutation on phorbol ester-induced translocation in NIH 3T3 cells

21 January 2018

1 reference

Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes.

21 January 2018

1 reference

Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester

21 January 2018

1 reference

Targeting protein kinase C and "non-kinase" phorbol ester receptors: emerging concepts and therapeutic implications

21 January 2018

1 reference

Wealth of opportunity - the C1 domain as a target for drug development

21 January 2018

1 reference

A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1

21 January 2018

1 reference

Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin

21 January 2018

1 reference

Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV

21 January 2018

1 reference

Identification, activity, and structural studies of peptides incorporating the phorbol ester-binding domain of protein kinase C.

21 January 2018

1 reference

Toward the identification of selective modulators of protein kinase C (PKC) isozymes: establishment of a binding assay for PKC isozymes using synthetic C1 peptide receptors and identification of the critical residues involved in the phorbol ester bi

21 January 2018

1 reference

Aplysiatoxin and debromoaplysiatoxin, constituents of the marine mollusk Stylocheilus longicauda

21 January 2018

1 reference

Aplysiatoxin and debromoaplysiatoxin as the causative agents of a red alga Gracilaria coronopifolia poisoning in Hawaii.

21 January 2018

1 reference

Bromine Residue at Hydrophilic Region Influences Biological Activity of Aplysiatoxin, a Tumor Promoter

21 January 2018

1 reference

Estimation of tumor promoting activity and structure-function relationships of aplysiatoxins

21 January 2018

1 reference

A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.

21 January 2018

1 reference

Tumor initiators and promoters in the induction of Epstein—Barr virus

21 January 2018

1 reference

Isolation and structure of bryostatin 1

21 January 2018

1 reference

Synthesis of bryostatin 7

21 January 2018

1 reference

Total Synthesis of Bryostatin 2

21 January 2018

1 reference

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

21 January 2018

1 reference

Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MED.20220

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22539107%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference